Jump Financial, LLC Alkermes Plc. Transaction History

Jump Financial, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 21, 2024	SELL	$27.17 - $31.97 $5.89 Million - $6.93 Million	-216,871 Reduced 92.83%	16,741 $468,000
Q3 2023 Nov 07, 2023	SELL	$27.17 - $31.97 $5.89 Million - $6.93 Million	-216,871 Reduced 92.83%	16,741 $468,000
Q2 2023 Oct 21, 2024	BUY	$28.34 - $33.63 $6.62 Million - $7.86 Million	233,612 New	233,612 $7.31 Million
Q2 2023 Aug 07, 2023	BUY	$28.34 - $33.63 $6.62 Million - $7.86 Million	233,612 New	233,612 $7.31 Million
Q4 2022 Feb 13, 2023	SELL	$21.94 - $26.24 $854,760 - $1.02 Million	-38,959 Reduced 25.86%	111,689 $2.92 Million
Q3 2022 Nov 07, 2022	SELL	$22.0 - $31.87 $177,584 - $257,254	-8,072 Reduced 5.09%	150,648 $3.36 Million
Q2 2022 Aug 09, 2022	BUY	$26.4 - $30.54 $4.19 Million - $4.85 Million	158,720 New	158,720 $4.73 Million

358

180M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.12B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.